Placebo + IBI362

Phase 3Recruiting

0 views this week 0 watching⚡ Active💉Featured in GLP-1 & Metabolic Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Adolescents With Obesity or Overweight With Weight-Related Comorbidities

Conditions

Adolescents With Obesity or Overweight With Weight-Related Comorbidities

Trial Timeline

Dec 29, 2025 → Oct 31, 2028

NCT ID

NCT07255209

About Placebo + IBI362

Placebo + IBI362 is a phase 3 stage product being developed by Innovent Biologics for Adolescents With Obesity or Overweight With Weight-Related Comorbidities. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07255209. Target conditions include Adolescents With Obesity or Overweight With Weight-Related Comorbidities.

What happened to similar drugs?

0 of 1 similar drugs in Adolescents With Obesity or Overweight With Weight-Related Comorbidities were approved

Approved (0) Terminated (0) Active (1)

🔄rizatriptan benzoateOrganonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07255209	Phase 3	Recruiting	Dec 29, 2025	Oct 31, 2028	Adolescents With Obesity or Overweight With Weight-Related Comorbidities
NCT06937749	Phase 2	Recruiting	Jul 1, 2025	Jul 22, 2027	Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT05607680	Phase 3	Completed	Nov 14, 2022	Apr 16, 2024	Obesity Or Overweight

Competing Products

3 competing products in Adolescents With Obesity or Overweight With Weight-Related Comorbidities

See all competitors

Product	Company	Stage	Hype Score
Lorcaserin	Eisai	Phase 1	29
IBI362 + IBI362 placebo	Innovent Biologics	Phase 1	29
rizatriptan benzoate	Organon	Phase 3	34